1. Public Health Service Act, July 1, 1944, Chap. 373, Title III, Sec. 351, 58 Stat. 702, currently codified at 42 U.S.C., Sec. 262
2. Rauch S, Jasny E, Schmidt KE, Petsch B (2018) New vaccine technologies to combat outbreak situations. Front Immunol 9:1963. https://doi.org/10.3389/fimmu.2018.01963
3. Poveda C et al (2019) Establishing preferred product characterization for the evaluation of RNA vaccine antigens. Vaccines 7:131
4. Ura T, Okuda K et al (2014) Developments in viral vector-based vaccines. Vaccines (Basel) 2(3):624–641
5. Janus T, Sitrin R, LeGrow K, Aunins A, Hagen A, Thornton R, Robinett R, Howson L (2003) Integrating CMC Document preparation into the development process for vaccine INDs. Available via BioPharm International: https://www.biopharminternational.com/view/integrating-cmc-document-preparation-development-process-vaccine-inds. Accessed 22 Mar 2015